OncView™ Podcast: Front-Line Management of Extensive-Stage SCLC

Podcast

This special edition of the “Oncology Peer Review On-The-Go” podcast hosts Mark Socinski, MD, who discusses important factors in treating and managing extensive-stage small cell lung cancer, and details information from the IMpower133 trial.

As part of the OncView™ video series, CancerNetwork® spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida, about updates in the management of extensive-stage small cell lung cancer (ES-SCLC).

In the video series, Socinski discussed the following:

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.